MedPath

Eosinophilic Cationic Protein as a Biomarker in Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Diagnostic Test: Eosinophilic Cationic Protein biomarker
Registration Number
NCT04008017
Lead Sponsor
Assiut University
Brief Summary

Chronic obstructive pulmonary disease is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. It is changed to acute exacerbation of Chronic obstructive pulmonary disease when respiratory symptoms worsen, beyond normal day-to-day variations, severely enough that changes in medication are required.

Inflammation is a core feature of acute exacerbation of Chronic obstructive pulmonary disease since it gives insight into the pathological changes causing an exacerbation. Eosinophils may play a significant role in airway inflammation in some patients with Chronic obstructive pulmonary disease.

Previous studies have indicated that eosinophilic airway inflammation is also associated with the development of severe acute exacerbation of Chronic obstructive pulmonary disease. Eosinophilic Cationic Protein has various biological activities, including antibacterial, antiviral, antiparasitic and neurotoxic functions, and it contributes to the regulation of fibroblast activity. Eosinophilic Cationic Protein also induces airway mucus secretion and interacts with the coagulation and complement systems. Eosinophilic Cationic Protein has been developed as a marker for eosinophilic disease and quantified in biological fluids including serum, bronchoalveolar lavage and nasal secretions. It is found in diseases such as allergic asthma and allergic rhinitis but also occasionally in other diseases. Only activated eosinophil granulocytes release the granule content and therefore the determination of Eosinophilic Cationic Protein concentration is a considerably more specific indicator of eosinophil inflammation than eosinophil granulocyte count in peripheral blood as serum Eosinophilic Cationic Protein levels increase during acute exacerbation of Chronic obstructive pulmonary disease

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
64
Inclusion Criteria
  • clinical features of Chronic obstructive pulmonary disease
  • spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity <70%) post bronchodilator.
Exclusion Criteria
  • Patients with bronchial asthma
  • Asthma -Chronic obstructive pulmonary disease overlap syndrome
  • Atopic patients
  • Pneumothorax
  • Congestive heart failure
  • Cancer of any kind
  • A history of major surgery in the preceding 4 weeks.
  • Patients undergoing mechanical ventilation or presenting with azotaemia (serum creatinine >1.5 mg/dl).

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
acute exacerbation of Chronic obstructive pulmonary diseaseEosinophilic Cationic Protein biomarkerpatients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator
stable Chronic obstructive pulmonary diseaseEosinophilic Cationic Protein biomarkerclinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator
Primary Outcome Measures
NameTimeMethod
The mean difference in the level of Eosinophilic Cationic Protein biomarker in the two study groups3 months

measurement by ELISA

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Assiut Faculty of Medicine

🇪🇬

Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath